The B7 family and other T cell co-stimulatory/co-inhibitory molecules are widely recognized as therapeutic targets for cancer immunotherapy. V-Set and Immunoglobulin domain containing (VSIG) proteins are members of the immunoglobulin protein superfamily and are increasingly recognized as potential immuno-oncology targets. In fact, R&D Systems scientists have identified VSIG3 as the ligand of VISTA-PD-1H (See poster, 1). Other unpublished results from our in-house research provide further evidence that the VSIG family plays an important role in T cell regulation.
R&D Systems exclusively offers bioactive VSIG proteins in both unlabeled and biotinylated formats for identifying binding partners and the development of novel therapies for immune checkpoint blockade.
Protein | Species | Source | Tag | Catalog # | Activity |
VSIG1 | Human | NS0 | Fc | 9708-VS | Suppresses IL-17 secretion |
Mouse | NS0 | Fc | 9645-VS | ||
VSIG2 | Human | NS0 | Fc | 9815-VS | Suppresses IL-17 secretion |
Mouse | NS0 | Fc | 9598-VS | ||
VSIG3 | Human | NS0 | Fc | 9229-VS | Binds VISTA/PD-1H (Catalog # 7126-B7) |
Human | CHO | Fc, Avi-tag | AVI9229 | ||
Human | NS0 | Fc, Biotin | BT9229 | ||
Human | CHO | Fc, C-term | 10075-VS | Suppresses IL-17 secretion | |
Human | CHO | Fc, N-term | 10074-VS | ||
Human | NS0 | His | 10806-VS | ||
Mouse | NS0 | Fc | 9367-VS | ||
VSIG4 | Human | CHO | His | 9816-VS | Suppresses IFN-gamma secretion |
Human | CHO | Fc | 9817-VS | ||
Mouse | NS0 | His | 9747-VS | ||
Mouse | NS0 | Fc | 4674-VS | Suppresses T cell proliferation | |
Cynomolgus Monkey | HEK293 | Fc | 10155-VS | Suppresses IFN-gamma secretion | |
Cynomolgus Monkey | HEK293 | His | 10807-VS | ||
VSIG4 Long isoform | Human | NS0 | Fc | 4646-VS | Binds complement component iC3b |
Human | HEK293 | Fc, Avi-tag | AVI4646 | ||
Human | NS0 | His | 9678-VS | Suppresses IFN-gamma secretion | |
VSIG8 | Human | CHO | Fc | 9200-VS | Inhibits CD3+ T cell proliferation and IL-2 secretion |
Cynomolgus Monkey | CHO | Fc | 11172-VS | Suppresses IL-2 secretion | |
Mouse | NS0 | Fc | 9204-VS | ||
TIGIT/ VSIG9/ VSTM3 |
Human | HEK293 | Fc | 9464-TG | Binds CD155/PVR (Catalog # 2530-CD) |
Human | CHO | Fc | 7898-TGB | Binds CD155/PVR (Catalog # 2530-CD) | |
Human | CHO | His, Avi-tag | AVI11124 | Binds CD155/PVR (Catalog # 2530-CD) | |
Human | CHO | His | 9525-TG | Binds CD155/PVR Fc (Catalog # 9174-CD) | |
Mouse | NS0 | Fc | 7267-TG | Binds CD155/PVR (Catalog # 6909-CD) | |
Cynomolgus Monkey | HEK293 | Fc | 9380-TG | Binds CD155/PVR (Catalog # 2530-CD) | |
VSIG10 | Mouse | NS0 | Fc | 9604-VS | Suppresses IL-17 secretion |
VSIG10L | Human | HEK293 | His | 9599-VS | Suppresses IFN-gamma Secretion |
Human | HEK293 | Fc | 9600-VS |
. | ||
Recombinant Human VSIG3 binds to Recombinant Human VISTA/PD-1H in a functional binding ELISA. The concentration of VSIG3 that produced 50% optimal binding was 0.25 mg/mL (3.4 nM). | Recombinant Human VSIG3 (Catalog # 9229-VS) inhibits anti-CD3 antibody induced IL-17 secretion in human PBMCs. The ED50 for this effect is 1-6 ug/mL. | Recombinant Human VSIG-10L (Catalog # 9600-VS) inhibits IFN-gamma secretion by PBMCs in the presence of anti-CD3 antibody. The ED50 for this effect is 1-6 µg/mL. |
. | ||
Recombinant Human VSIG8 inhibits anti-CD3 induced human CD3+ T cell proliferation. For more information on VSIG8's role as a coinhibitory ligand, see our poster. | Recombinant Cynomolgus Monkey VSIG4 (Catalog # 10155-VS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions showing bands at 67-76 kDa and 130-150 kDa, respectively. |
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions
Mechanisms of Regulatory T Cell-Mediated Suppression